Notch Therapeutics, an early-stage cancer cell therapy biotech, will close its Vancouver lab and part ways with “some of our talented colleagues,” the startup posted via LinkedIn in recent days.
The Pacific Northwest and Canadian biotech formed in 2018 with the intent of “industrializing the production of cells,” signed an off-the-shelf cell therapy pact with Allogene in 2019 and then disclosed an $85 million Series A in February 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.